Peer Review History
| Original SubmissionMarch 28, 2025 |
|---|
|
Dear Dr. Pollock, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Aug 24 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Yi Ding Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Thank you for stating the following in the Acknowledgments Section of your manuscript: “This work was supported in part by grants from the New Frontiers in Research Fund (Exploration grant, CLP) and the Michael Smith Foundation for Health Research (Scholar Award, CLP).” We note that you have provided additional information within the Acknowledgements Section that is not currently declared in your Funding Statement. Please note that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: “This work was supported in part by grants from the New Frontiers in Research Fund (Exploration grant, CLP) and the Michael Smith Foundation for Health Research (Scholar Award, CLP).” Please include your amended statements within your cover letter; we will change the online submission form on your behalf. 3. Thank you for stating the following financial disclosure: ““This work was supported in part by grants from the New Frontiers in Research Fund (Exploration grant, CLP) and the Michael Smith Foundation for Health Research (Scholar Award, CLP).”” Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 4. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process. 5. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. 6. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: This is an automated report for PONE-D-25-16381. This report was solicited by the PLOS One editorial team and provided by ScreenIT. ScreenIT is an independent group of scientists developing automated tools that analyze academic papers. A set of automated tools screened your submitted manuscript and provided the report below. Each tool was created by your academic colleagues with the goal of helping authors. The tools look for factors that are important for transparency, rigor and reproducibility, and we hope that the report might help you to improve reporting in your manuscript. Within the report you will find links to more information about the items that the tools check. These links include helpful papers, websites, or videos that explain why the item is important. While our screening tools aim to improve and maintain quality standards they may, on occasion, miss nuances specific to your study type or flag something incorrectly. Each tool has limitations that are described on the ScreenIT website. The tools screen the main file for the paper; they are not able to screen supplements stored in separate files. Please note that the Academic Editor had access to these comments while making a decision on your manuscript. The Academic Editor may ask that issues flagged in this report be addressed. If you would like to provide feedback on the ScreenIT tool, please email the team at ScreenIt@bih-charite.de. If you have questions or concerns about the review process, please contact the PLOS One office at plosone@plos.org. Reviewer #2: The authors examine, in stroke patients, how objective and subjective (RPS, related to the lab balance challenge) measures of balance relate to Electrodermal arousal (EDA), with the ultimate goal of understanding which objective measures best predict RPS. This is important since self efficacy at balance contributes to the quality of life for stroke patients. Objective and subjective measures of balance were related, while EDA was not a useful indicator (significant for RPS but small effect size). Individual effects explained even more variance in RPS, suggesting that additional factors may be critical when trying to understand and enhance the sense of self-efficacy in maintaining balance. The authors need to do analyses including ABC, the subjective sense of balance in real life. In part since this showed a sex difference. This metric would seem, from first principle, to potentially have important implications for quality of life. The discussion of arousal is incomplete (e.g., l.395-). EDA is only one arousal measure, with heart rate variability, cortisol, and others also capturing arousal patterns that are missed with EDA. Thus, the authors should not overstate that arousal did not relate to RPS, since only one facet of arousal was measured. The abstract needs to be rewritten to be clearer, especially about what higher or lower in different measures indicate, and the interpretation of the relation between measures. l.48 “repeat exposure:” does this mean first vs second test day? Is there precedent that that d1 and d2 of testing would be different? l.57-58, 313- is unclear for “decreases in participant RPS scores relative of 2.80.” Does this mean that greater objective balance associates with reduced subjective balance? l.63-64 what %variance explained by individual effects? l.206 calculating baseline for EDR from 4 sec around the minimum could bias baseline measures, e.g. magnifying small dips from noise in the recording. While a reference is cited, this baseline measure requires clearer justification. l.214 normalizing EDR to the maximum also needs good justification. Many studies use raw EDR, and normalizing could washout e.g. where people with larger EDR have less balance self-efficacy. l.253 are Tukey post hoc corrected for multiple comparisons? l.184-185, 300- Please discuss more the concern is that removing measures in CBM will skew the remaining findings. Minor l.137 change to “; and (3)” ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.
|
| Revision 1 |
|
Dear Dr. Pollock, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.
Please submit your revised manuscript by Dec 19 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Luca Citi, PhD Academic Editor PLOS ONE Journal Requirements: 1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #2: (No Response) Reviewer #3: All comments have been addressed Reviewer #4: All comments have been addressed Reviewer #5: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: I Don't Know ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: (No Response) Reviewer #5: Yes ********** Reviewer #2: now good. The paper provides new data, which are somewhat preliminary but help advance use of biometrics as indicators for risks like falls during stroke Reviewer #3: The authors present the results of a potentially interesting revised version of an observational clinical study showing that ability to perform a walking balance task (CB&M task performance score) and the underlying physiological arousal response are independent predictors of perception of balance in people with chronic stroke as measured by the Rate of Perceived Stability. The study can improved if the following minor considerations are addressed: 1.Due to the small size of the study (n=27 patients) the title should clearly mention “preliminary findings”. 2.It would be useful to clearly mention in the Introduction section that women differ from men in the distribution of risk factors and stroke subtypes, stroke severity, and outcome (see data and comment on the study published in Cerebrovasc Dis 2025;54(1):11-19. doi: 10.1159/000536436. Epub 2024 Jan 29. PMID: 38286114). 3.It would be interesting to know the different stroke subtypes (cardioembolic stroke, lacunar infarct, infarct of unusual etiology, essential cerebral infarct, atherothrombotic infarct, intracerebral hemorrhage) in the study population. 4.It would be interesting to add in the text that an essential line of future research would be precisely to evaluate the impact of the differences on this topic between lacunar and non-lacunar ischemic strokes. This recommendation is because the pathophysiology, prognosis, and clinical features of ischemic lacunar strokes are different from other acute ischemic cerebrovascular diseases (see and include this supporting reference: Neuroepidemiology 2010;35:231-236), 5.A brief final comment on other possible lines of future research on the presented topic would be appreciated. 6.Please check references #26, #34 and #46 Reviewer #4: Line 97 to 99 there is no figure but the figure caption is there Was participant subjected to walking 10 meters walk this before recruitment of it was base on self report? Line 249-252Move to the section where you explained the CB&M before this paragraph Linear Mixed Models line 253-261 is unclear, and I am having difficulty following exactly what was done. Please clearly specify the exposure variable(s) and the fixed effects included in your model. In addition, clarify how the random intercept was formulated and what grouping structure it represents. "response). Power for 274 the mediation pathway was approximated by calculating power for each constituent effect (CB&M 275 task performance→ physiological arousal; physiological arousal → RPS) using Cohen’s d and the 276 pwr package, then combining them. Observed, standardized, and hypothetical medium-sized 277 effects (d = 0.35) were evaluated for sensitivity." -The approach described here approximates power by calculating it separately for each constituent effect and then combining them. This should be noted as a limitation, because the true power for the mediation pathway is typically lower, both paths must be significant for the indirect effect to hold. As a result, this approach may overestimate the true mediation power. Reviewer #5: Thank you for your responses. All the issues requested by previous reviewers have been corrected. I only found one question that I couldn't find an answer to. Comment 3: l.48 “repeat exposure:” does this mean first vs second test day? Is there precedent that that d1 and d2 of testing would be different? ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #2: No Reviewer #3: Yes: Dr. Adrià Arboix Reviewer #4: No Reviewer #5: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. |
| Revision 2 |
|
Relationship between the rate of perceived stability, electrodermal activity and task performance during balance challenges in chronic stroke PONE-D-25-16381R2 Dear Dr. Pollock, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support . If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Luca Citi, PhD Academic Editor PLOS ONE |
| Formally Accepted |
|
PONE-D-25-16381R2 PLOS One Dear Dr. Pollock, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Luca Citi Academic Editor PLOS One |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .